Flupirtine in pain management: pharmacological properties and clinical use
- PMID: 20839897
- DOI: 10.2165/11536230-000000000-00000
Flupirtine in pain management: pharmacological properties and clinical use
Abstract
Flupirtine is a centrally acting, non-opioid analgesic that is available in a number of European countries for the treatment of a variety of pain states. The therapeutic benefits seen with flupirtine relate to its unique pharmacological properties. Flupirtine displays indirect NDMA receptor antagonism via activation of potassium channels and is the first representative of a pharmacological class denoted the 'selective neuronal potassium channel openers'. The generation of the M-current is facilitated by flupirtine via the opening of neuronal Kv7 potassium channels. The opening of these channels inhibits exaggerated neuronal action potential generation and controls neuronal excitability. Neuronal hyperexcitability is a physiological component of many pain states such as chronic pain, migraine and neurogenic pain. Although large-scale clinical trials are lacking, the clinical trial database available to date from smaller-scale studies, together with extensive clinical experience, indicate that flupirtine effectively reduces chronic musculoskeletal pain, migraine and neuralgias, amongst other types of pain. In addition, flupirtine produces, at recommended clinical doses, muscle-relaxing effects in the presence of abnormally increased muscle tension. Its analgesic and muscle-relaxant properties were comparable to tramadol and chlormezanone, respectively, in two prospective trials in patients with lower back pain. Cytoprotective, anti-apoptotic and antioxidant properties have also been associated with flupirtine use in a small number of studies to date. When provided as combination therapy with morphine, flupirtine increases the antinociceptive activity of morphine 4-fold. Flupirtine displays superior tolerability when compared with tramadol and pentazocine. The most common adverse effects associated with flupirtine use are drowsiness, dizziness, heartburn, dry mouth, fatigue and nausea. With respect to its molecular structure, mechanism of action and adverse event profile, flupirtine is a unique drug. Flupirtine is an analgesic with many potential therapeutic benefits that may prove useful in the treatment of many disease states.
Similar articles
-
Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states.Drugs. 1993 Apr;45(4):548-69. doi: 10.2165/00003495-199345040-00007. Drugs. 1993. PMID: 7684675 Review.
-
Flupirtine antinociception in the rat orofacial formalin test: an analysis of combination therapies with morphine and tramadol.Pharmacol Biochem Behav. 2011 Jan;97(3):544-50. doi: 10.1016/j.pbb.2010.11.002. Epub 2010 Nov 10. Pharmacol Biochem Behav. 2011. PMID: 21073890
-
Efficacy and tolerability of flupirtine in subacute/ chronic musculoskeletal pain - results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials.Int J Clin Pharmacol Ther. 2011 Nov;49(11):637-47. doi: 10.5414/cp210000. Int J Clin Pharmacol Ther. 2011. PMID: 22011688 Clinical Trial.
-
Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain.Pharmacology. 2020;105(7-8):471-476. doi: 10.1159/000505934. Epub 2020 Feb 14. Pharmacology. 2020. PMID: 32062659
-
Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.Expert Opin Pharmacother. 2009 Jun;10(9):1495-500. doi: 10.1517/14656560902988528. Expert Opin Pharmacother. 2009. PMID: 19505216 Review.
Cited by
-
Flupirtine drug-induced liver injury in a patient developing acute liver failure.BMJ Case Rep. 2018 Mar 9;2018:bcr2017223329. doi: 10.1136/bcr-2017-223329. BMJ Case Rep. 2018. PMID: 29523613 Free PMC article.
-
Between guidelines and clinical trials: evidence-based advice on the pharmacological management of non-specific chronic low back pain.BMC Musculoskelet Disord. 2023 May 30;24(1):432. doi: 10.1186/s12891-023-06537-0. BMC Musculoskelet Disord. 2023. PMID: 37254090 Free PMC article. Review.
-
Detrusor Smooth Muscle KV7 Channels: Emerging New Regulators of Urinary Bladder Function.Front Physiol. 2020 Sep 16;11:1004. doi: 10.3389/fphys.2020.01004. eCollection 2020. Front Physiol. 2020. PMID: 33041840 Free PMC article. Review.
-
The indirect NMDAR inhibitor flupirtine induces sustained post-ischemic recovery, neuroprotection and angioneurogenesis.Oncotarget. 2015 Jun 10;6(16):14033-44. doi: 10.18632/oncotarget.4226. Oncotarget. 2015. PMID: 26050199 Free PMC article.
-
[Non-opioid pain medication in the elderly].Schmerz. 2015 Aug;29(4):371-9. doi: 10.1007/s00482-015-0032-2. Schmerz. 2015. PMID: 26242359 Review. German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical